Boruikang Technology has launched its initial public offering (IPO) process with the goal of raising 2.5 billion yuan to further develop its brain-computer interface (BCI) technology. The company, which has generated over 100 million yuan in revenue from its non-invasive BCI products, is currently grappling with substantial financial losses. Its leading product, the NEO brain-computer interface, has recently gained regulatory approval; however, it faces significant challenges in the commercialization phase, particularly regarding market acceptance and the sustainability of its operations.
Leave a comment